Treatment of Feline Mammary Fibroepithelial Hyperplasia with the Combination of Aglepristone and Cabergoline

Abstract

A case of fibroepithelial mammary hyperplasia in a two years old, intact, tabby female cat that showed oestrus 1 month ago was treated with the combination of aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) administrations. On the day of treatment, serum progesterone concentration was detected as 2,96 ng/ml and serum oestradiol concentration was below 5,0 pg/ml. The cat was treated with subcutaneous (SC) injections of aglepristone (Alizine, Virbac®) 15 mg/kg body weight (b.w.) on two subsequent days per week for three weeks and 5 µg/kg b.w per a day, per os (PO) cabergoline (Galastop, Ceva®) administration was accompanied to this treatment on the first week for seven days. On the examination at the end of the third week, there was a marked regression of the mammary glands and the milk secretion ceased. Six weeks after the initiation of treatment, mammary glands were completely regressed and serum progesterone and oestradiol concentrations were 0.142 ng/ml, and <5pg/ml respectively. It is determined that in such cases which is associated with milk secretion, successful results can be achieved by using aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) together. Key Words: Fibroepithelial hyperplasia, aglepristone, cabergoline